Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Related Terms
Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a EBITDA Margin % of 21.57% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #174 out of 944 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % too high?
Biocytogen Pharmaceuticals (Beijing) Co's current EBITDA Margin % is 21.57%. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #174 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #174 out of 944 companies for EBITDA Margin %. This places Biocytogen Pharmaceuticals (Beijing) Co in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current EBITDA Margin % is 21.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €4.52 — trading 29.1% above its estimated fair value. The current EBITDA Margin % is 21.57%. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current EBITDA Margin % is 21.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €4.52 is trading 29.1% above its estimated GF Value™ of €3.50.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Modestly Overvalued.
Key valuation signals for FRA:I54:
EBITDA Margin %: 21.57%
GF Value™: €3.50 vs. price of €4.52 (29.1% above fair value)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score
Get the complete analysis for FRA:I54
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
